Health · 6 views
ESMO: New analysis reinforces survival benefits of targeted therapy for advanced pancreatic cancer
A new analysis of a phase 3 clinical trial found that the targeted drug daraxonrasib improved survival compared with standard chemotherapy across multiple groups of patients with advanced pancreatic cancer, including those with different…
AI Summary
A phase 3 trial analysis showed that the targeted drug daraxonrasib improved survival versus standard chemotherapy in patients with advanced pancreatic cancer. The benefit applied across multiple patient groups, including those with different RAS mutations and those without an identified RAS mutation. The results were presented at the European Society for Medical Oncology Congress by Dr. Zev Wainberg of UCLA Health. They build on earlier RASolute 302 data, where daraxonrasib produced a median overall survival of 13.2 months compared with 6.7 months for standard chemotherapy.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- 5 great cardio workouts you can do at homeContinue reading
- Supplement Shows Promise for Improving Cancer-Related Cognitive ImpairmentContinue reading
- Study identifies potential new treatment targets for the most common type of bowel cancerContinue reading
- STAT+: Diabetes association says ‘threat’ preceded members’ ejections, but admits policies were unclearContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow